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1083-8791Protection of people from what was then termed bone
marrow syndrome, resulting from radiation exposure,
would become a focus of the Institute’s research efforts for
many decades.Dirk van Bekkum was a pioneer of bone marrow
transplantation who helped to establish and shape our
discipline. His discoveries led the way to the clinical use of
transplantation. Dirk was born in Batavia, the Dutch West
Indies (Djakarta, Indonesia today) where his father was a
civil servant. He was educated at Leiden University in The
Netherlands and received his MD in 1950. He then studied
biochemistry at Oxford with Sir Rudolph Peters and
returned to The Netherlands to complete his PhD, cum
laude, on the effect of corticosteroids on muscle develop-
ment in 1952. In 1960, he founded the Radiobiological
Institute of the Dutch Health Organization TNO in Rijswijk.
Protection against radiation exposure had become a hot
research topic after the atomic bombs were dropped on
Hiroshima and Nagasaki at the end World War II.quests: Robert Peter Gale, Department of
don, UK. (or) Bob Löwenberg MD, PhD,
us University Medical Center, Rotterdam,
erg@erasmusmc.nl (B. Löwenberg),
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15.08.003Dirk’s research contributions to the ﬁeld of trans-
plantation were fundamental. It is difﬁcult to imagine, but at
that time, the basis of the protective effect of a spleen cell or
bonemarrow transplantation after total body radiationwas a
mystery. Was it a humoral factor (hormone) in the donor
bone marrow that protected and supported recovery of
endogenous bone marrow cells, or was it something else? In
1956, van Bekkum and colleagues, simultaneously with sci-
entists in Oxford and San Francisco, reported data supporting
the notion that cells from the graft repopulated the host bone
marrow tissue and were responsible for hematopoietic re-
covery from radiation-induced aplasia. They termed the
outcome chimerism after the mythological Greek beast part
lion, part goat, part snake. van Bekkum and colleagues then
showed that the degree of donor engraftment and of
chimerism depend not only on the intensity of myeloid and
lymphoid suppression (conditioning) of the recipient, but
also on numbers of spleen and/or bone marrow cells trans-
planted and on genetic relatedness between donor and
recipient. They based the latter conclusion on comparisons of
outcomes of isogeneic, syngeneic, and allogeneic trans-
plantations. A wasting syndrome, then called secondary dis-
ease, characterized by weight loss, diarrhea, skin and fur
abnormalities, and death had been described in mice sur-
viving after a transplantation, but the etiology was unknown.
Using parent to F1 hybrid and the reverse donor-recipient
transplantation combinations in mice, Dirk and colleagues
proved that the secondary disease phenomenon was caused
by graft-versus-host disease (GVHD), ie, donor immune cells
in the graft reacting against recipient tissues. They also
recognized that there is a quantitative relationship between
numbers of transplanted, allogeneic immune cells and the
incidence and severity of GVHD. Dirk discovered bone
marrow from subhuman primates (Rhesus monkeys), like
humans, contains many more immune cells, able to induce
GVHD, compared with rodent bone marrow. This explains
the marked differences in patterns of GVHD between these
species. van Bekkum showed that in mice, and later in Rhesus
monkeys and beagles, that selective elimination of PHA-
reactive lymphocytes from the allogeneic graft could
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his team showed antilymphocyte serum could be used to
prevent or treat GVHD in mice and monkeys. This led to
diverse uses of antilymphocyte serum in the transplantation
setting. Another innovative ﬁeld he pioneered was gnotobi-
ology. van Bekkum and colleagues showed that host
gastrointestinal ﬂora, especially Gram-negative organisms,
are important in the development of GVHD. Under some
experimental conditions, GVHD could be prevented in germ-
freemice. They also showed that inmice, dogs, andmonkeys,
bacterial decontamination before transplantation would
reduce the incidence and severity of GVHD. This led to many
of our current antimicrobial practices.
In 1967, van Bekkum, Jon van Rood, Leo Jan Dooren, and
Jaak Vossen performed the ﬁrst successful allo-
transplantation in humans in an infant with severe com-
bined immune deﬁciency (SCID). SCID was a lethal disease
with no effective therapy, and previous transplantation at-
tempts in several settings and diseases had failed. Based on
their observations in hematopoietic chimeras, neonatally
thymectomized animals, and autopsy studies of children
with SCID, van Bekkum and his team postulated that SCID
resulted from a hematopoietic stem cell defect, resulting in
failure of these cells to mature in the thymus into immune
competent lymphocytes. They reasoned that children with
SCID could be cured by providing a transplant of normal
hematopoietic stem cells. The transplantationwas donewith
bone marrow from an HLA-identical sibling, separated on a
discontinuous density gradient to deplete cells able to cause
GVHD, and the child was nursed in a laminar air ﬂow room.
Simultaneously, teams in Minneapolis (Robert Good, Richard
Gatti, Hilaire Meuwissen, Richard Hong, and others) and
Madison (Fritz Bach, Mortimer Bortin, and others) were also
successful in curing children with SCID or the closely related
Wiskott-Aldrich syndrome. Transplantation has became a
standard treatment for children with SCID.
In 1971, after developing albumin density gradients and
ﬂuorescence activated cell sorting to concentrate stem cells,
Van Bekkum and collaborators deﬁned the morphological
and submicroscopic features of hematopoietic stem cells in
highly puriﬁed bone marrow fractions.
The Radiobiological Institute, under van Bekkum’s lead-
ership, would become one of the leading scientiﬁc centers,
with important programs in bone marrow transplantation,
stem cell, and experimental leukemia research. The atmo-
sphere in the Institute bore the typical van Bekkum stamp.
There was an ambitious spirit of team work and scientiﬁc
entrepreneurship. Evening seminars, preceded by Indone-
sian rijsttafel (enthusiastically adopted by the Dutch), were
famous and attracted attendees from far away, who did not
want to miss the presentations and discussions (much less
the food). There was much fun and humor in the air of the
Institute. Cabarets were produced at party evenings; Dirk
would play major roles. Table tennis during lunch wouldoffer a popular break to staff, PhD and post-doctoral stu-
dents, and technicians. Dick was a ping pong champion and
enjoyed tennis, skiing, and swimming.
The international workshops Dirk organized at the Insti-
tute were intended to bring together scientists with
opposing views and/or conﬂicting data. These were memo-
rable. For instance, for the workshop on in vitro colony-
forming cells held in 1971, in the early days of the
emerging ﬁeld of progenitor cell research (before the mo-
lecular cloning of the growth factors), researchers such as
Ray Bradley, Don Metcalf, Malcolm Moore, Dov Pluznik,
Ernest McCullough, John Till, Fred Stohlman, and others
brought their culture systems with their impure ingredients
(conditioned media, tissue extracts) to the Institute to do
experiments and make direct comparisons.
In 1967, van Bekkum and Marco de Vries published Ra-
diation Chimeras, the Bible of experimental bone marrow
transplantation. The book describes the fundamentals of
bone marrow transplantation, concepts of hematopoietic
chimerism, GVHD, and potential clinical applications of
transplantations. The authors predicted, 50 years ago, almost
all areas we work in today!
Dirk had a unique personality. He liked debate and would
challenge any speaker, regardless their position. However, he
was straight and stimulated a critical discussion. He wanted
to bring the real issues to the surface in the interest of clear
thinking and conclusions. Beneath it all, he was kind, warm-
hearted, and encouraging to students, colleagues, and
friends.
Dirk was thementor to one of us (B.L.). The ﬁrst time I met
with him was almost 45 years ago. In 1971, Professor van
Bekkum’s secretary led me to his ofﬁce. I was 25 years old
and had just graduated from medical school. We immedi-
ately got into a heated discussion over my possible research
project. On leaving, I was convinced he would never accept
my application for a postdoctoral position. But he did. That
meeting was the beginning of my research career in hema-
tology and of a lasting professional relationship and
friendship.
Dirk received various honors. He was an elected member
of the Dutch Royal Academy of Arts and Sciences and a
Knight of the Royal Order of the Lion of The Netherlands, a
founder of the European Organization for Research on
Treatment of Cancer, European Bone Marrow Trans-
plantation Group, the International Bone Marrow Trans-
plantation Registry (now CIBMTR), the International Society
of Experimental Hematology, the Dutch Society of Immu-
nology, recipient of a Fogarty Scholarship from the US Na-
tional Institutes of Health, and an honorary member of the
Dutch Society of Gene Therapy and Cell Biology.
Dick is survived by his wife Ada, 4 daughters, 11
grandchildren, and 7 great grandchildren with more en
route. He will be greatly missed by many people
everywhere.
